June 22, 2017 3:05 PM ET


Company Overview of Alcyone Lifesciences, Inc.

Company Overview

Alcyone Lifesciences, Inc., a medical device company, focuses on development of novel treatment modalities for chronic neurological conditions. The company develops micro-fabricated delivery systems, including Alcyone MEMS (microelectromechanical system) Cannula (AMC) system, a neuro-ventricular cannula and accessories that enable neurosurgeons to select a target, navigate the AMC precisely to the target, and observe in real-time the precision delivery of the therapeutic agent under intra-procedural MRI guidance. It offers solutions for the treatment of various neurologic conditions, including brain tumor, hydrocephalus, epilepsy, and neurodegenerative diseases. The company was founded in 20...

250 Jackson Street

Unit 494 Mill No. 5 Building

Lowell, MA 01852

United States

Founded in 2010



Key Executives for Alcyone Lifesciences, Inc.

Founder, Chief Executive Officer, President and Director
Co-Founder, Consulting Chief Medical Officer and Member of Scientific Advisory Board
Vice President of Regulatory, Quality and Clinical Affairs
Age: 48
Compensation as of Fiscal Year 2016.

Alcyone Lifesciences, Inc. Key Developments

Alcyone Lifesciences, Inc. Announces Clinical use of its ReFlow System for the Treatment of Hydrocephalus

Alcyone Lifesciences, Inc. has announced the clinical use of its ReFlow System in four patients treated to date in an institutional review board (IRB)-approved study at Boston Children's Hospital. Hydrocephalus is a condition in which an excess of cerebrospinal fluid (CSF) accumulates in the ventricles and can increase the pressure in the brain creating a life threatening condition. CSF shunts are implantable devices inserted by neurosurgeons to treat hydrocephalus. The youngest patients seem at high risk of shunt failure, many requiring numerous revision surgeries by adolescence. Alcyone's patented ReFlow™ System, comprised of a unique Flusher and Ventricular Catheter with relief membrane as components of a CSF shunt system, is designed to address one of the two most common and frustrating problems with CSF shunts resulting in emergency intervention, namely obstructions of the ventricular catheter. To extend the life of these shunts and avoid emergency shunt revision, retrograde flushing of flow regulating valves and invasive shunt taps have been employed by neurosurgeons in attempt to unblock ventricular catheters. However, these methods have been inconsistent, at best, and can introduce risk of infection (the other most common CSF shunt problem) and damage to the flow-regulating valve. The core concept to realize a fully implantable, non-invasive means that can consistently unblock an occluded ventricular catheter came from an earlier IRB study also performed at Boston Children's Hospital (BCH).

Alcyone Lifesciences, Inc. Presents at Boston CEO Conference, May-31-2016 03:30 PM

Alcyone Lifesciences, Inc. Presents at Boston CEO Conference, May-31-2016 03:30 PM. Venue: Four Seasons Boston, 200 Boylston Street, Boston, MA 02116, United States. Speakers: P. J. Anand, Founder, Chief Executive Officer, President and Director.

Nanologica, Alcyone Lifesciences to Collaborate Via Licensing Agreement

Nanologica announced that it has entered into a License and Collaboration Agreement with Alcyone Lifesciences to develop a novel therapeutic platform named Abela; 'to breathe' in Hebrew. The partners want to combine Nanologica's NLAB Silica™ with Alcyone's proprietary drug delivery platform technology. The goal is to develop and commercialize through partnership with biopharma a treatment of certain motor neuron disorders, including Amyotrophic Lateral Sclerosis (ALS), based on targeted and sustained delivery of trophic factors in combination with embryonic stem cell derived cells. The role of trophic factors is to rescue degenerating neurons or to support survival of transplanted stem cells in patients with ALS or other motor neuron disorders. According to the License and Collaboration Agreement, Alcyone will operate the Abela program and will be responsible for further development and financing of the program through collaboration with biopharma. ALS is a fatal neurodegenerative disease that affects nerve cells in the brain and spinal cord. It usually starts with loss of control of limbs or difficulties in swallowing related to muscle weakness. Most patients suffer a rapid decline in motor function and die within 2-5 years due to inability to breathe in most cases. There is currently no cure for ALS. Only one drug has been approved for the treatment of ALS, with a limited clinical benefit of slowing down the progression of disease. There are currently more than 70,000 ALS patients1,2 in the United States and Europe alone who would benefit from a new therapy. In previous work, Nanologica in collaboration with Professor Elena N Kozlova (Uppsala University) demonstrated sustained delivery of trophic factors for survival and functional differentiation of stem cells by using nanoporous silica particles.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Alcyone Lifesciences, Inc., please visit www.alcyonels.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.